br/the 17th world congress of cardiology management committee chairman, academician of Chinese academy of engineering GaoRunLin
erne the vice-chairmen shall MaChangSheng
in the 17th world congress of cardiology (WCC), reporters heard a lot of prevention interventions, diagnosis and treatment strategies new idea, also heard & ldquo; Stem cell therapy & rdquo; , & ldquo; Artificial heart & rdquo; This kind of fresh word, this period, "life times" reporter dialogue authoritative expert, please they took us into the world a new frontier of cardiology.
reporter: this world congress of cardiology, let you touch the deepest is what?
GaoRunLin: world congress of cardiology (WCC) is heart disease ldquo; academic & Olympic conference & rdquo; , is the international academic exchange between the important window. This congress unveiled a set of data, the shows that developing countries stroke incidence, mortality has been beyond the developed countries. Cardiovascular disease has become a worldwide disaster, regardless of gender, regardless of the city or the country is the first. For the first time in Asia and China WCC held at present in China, as well as that of cardiovascular fields faced problem is serious, looming. We have unprecedented for cardiovascular disease, through stress of lifestyle intervention, control smoking, high blood pressure, high cholesterol, high blood sugar, obesity risk factors such as medical priority. Become In addition, the conference also discussed about women heart disease, has subverted that previous low morbidity, mortality, low female the idea.
MaChangSheng: this high level meeting to the internationalization of Chinese heart fields, the clinical doctors, researchers provided larger stage, more opportunities, make the world hear speech the voice of more Chinese. Can and world-top expert face-to-face communication, to itself is greatly improved.
reporter: at present, the world to treat heart disease, what new breakthrough the gap between China and the world have how old?
GaoRunLin: heart disease treatments include medication, interventional treatment and surgery. In recent years, some new drugs emerge, and after large-scale clinical trial have proven effective treatment of coronary heart disease, such as acute coronary syndrome, atrial fibrillation with a new antiplatelet agents, oral anticoagulants; New antihypertensive drug, etc. How to choose to coronary heart disease patients drug therapy, interventional therapy or bypass surgery, have evidence-based medical evidence, not only by experiences. Difficult surgery intervention to challenge, like percutaneous aortic valve replacement, makes some older age, not suitable for surgical patients have a chance to regain a new life. In addition, outside intervention into the heart of the site, such as application trans-catheter ablation renal artery sympathetic nerve, treatment resistant hypertension, this also reflected the crossover between disciplines. Again, conversion of medical research, accelerate basic disciplines, biomedical engineering research achievements to clinical applications are also very eye-catching transformation, such as artificial heart research is one of concern about the direction of the medical profession.
MaChangSheng: overall, traditional treatments have enter platform in the stable development period, the platform has a few little breakthrough, but the new technology, new found no 10 years ago that makes a person dazzling. Ten years ago, our treatment level and the developed countries differ 15 years, after all these years of pursued, the gap has narrowed to 3 & mdash; Five years, but the scientific research level is still large difference. This and basic research time cycle is long, the need to invest more funds, manpower, and national and social support has a direct relation.
reporter: China experts in the status of world heart study field?
GaoRunLin: in the past two or three years, China in cardiovascular epidemiological studies, especially the international cooperative research have not only brought the onset of Chinese population cardiovascular disease, death, risk factors and popular characteristic, but also to understand the difference between eastern and western crowd has provided valuable information. Practice in hypertension and myocardial infarction aspects of large-scale randomized clinical trial for cardiovascular disease, the treatment, and provides an important basis for foreign authority guidelines adopted. The traditional Chinese medicine for evidence-based medicine, mining motherland medicine treasure. In recent years, Chinese doctor actively participated in many large clinical trials worldwide, provides compatriots data. Clinically, cardiovascular interventional treatment in China is developing very fast every year, percutaneous coronary intervention mdash 25% increase in number; and 30%, last year made 24 million cases across the country after the United States, surgical, ranking second in the world, technology has become more and more mature. Now the main problem facing is standardization, the health ministry has through technology access and assessment, training system to regulate the technology. Congenital heart disease in interventional therapy technology or on the amount, whether are in a leading level. In addition, in recent years basic research has also made a lot of progress in the international famous magazine published a high level paper increases.
reporter: our medical, scientific research workers in which aspects should also work?
GaoRunLin: the level of our scientific research and developed countries still have obvious difference. Should make full use of cases more resources advantages, organize and implement a high level of clinical research, in addition to the government increased the investment outside, should strive for pharmaceutical factory and the support of private capital. In addition, should strengthen transformation medical research. Clinically, turn to problems found in basic research, basic research results better and faster into clinical application, serve the patients. In clinic, to reduce clinical practice guidelines with the gap of evidence-based medicine, this also is doctors around the world are faced with the problem, let evidence-based medicine, guide to better guide clinical, further improve the clinical treatment level. ▲
scale-up="clear"
